Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Immigrant and Minority Health
Published in: Journal of Immigrant and Minority Health 3/2019

01-06-2019 | Original Paper

Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community

Authors: Amber R. Tierney, William Huepfel, Aasma P. Shaukat, John R. Lake, Mark Boldt, Qi Wang, Mohamed A. Hassan

Published in: Journal of Immigrant and Minority Health | Issue 3/2019

Login to get access

Abstract

Hepatitis C treatment has rapidly evolved with the arrival of direct-acting antiviral therapy. Sustained virologic response (SVR) rates in clinical trials are high but it is unknown how this translates to the immigrant community. Data from December 2013 to September 2015 was collected from a Midwest academic and community practice with a large immigrant population. There were 802 patients with an overall SVR rate of 88%. Ledipasvir/sofosbuvir was associated with favorable response among genotype 1 and 4 patients compared to other regimens (p < 0.001 and p = 0.05). Factors associated with treatment failure included advanced liver disease, male gender, East African/Middle Eastern ethnicity, and non-compliance. Patients with genotype 4 had lower SVR rates than other genotypes (58% vs. 89%, p < 0.001), particularly among East Africans (40% vs. 82% for other ethnicities). Our SVR rate for genotype 4 infection is lower than clinical trials and may be related to cultural, biologic and socioeconomic factors.
Literature
1.
Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014;109(5):628–35.CrossRefPubMed
2.
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.CrossRefPubMed
3.
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603.CrossRefPubMed
4.
Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–92.CrossRefPubMed
5.
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65.CrossRefPubMed
6.
Zeuzem S, Dusheiko DM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.CrossRefPubMed
7.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.CrossRefPubMed
8.
Jacobson IM, Gordon SC, Kowdley KW, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.CrossRefPubMed
9.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMed
10.
Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385(9973):1098–106.CrossRefPubMed
11.
12.
Lopez-Velez R, Turrientes C, Guiterriez C, Mateos M. Prevalence of hepatitis B, C, and D markers in Sub-Saharan African immigrants. J Clin Gastroenterol. 1997;25(4):650–2.CrossRefPubMed
13.
Shire AM, Sandhu DS, Kaiya JK, et al. Viral hepatitis among somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proceed. 2012;87(1):17–24.CrossRef
14.
15.
Kamal SA, Nasser IA. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology. 2008;47(4):1371–83.CrossRefPubMed
16.
Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5, and 6. Aliment Pharmacol Ther. 2014;39:137–47.CrossRefPubMed
17.
Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040–6.CrossRefPubMed
18.
Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–5.CrossRefPubMed
19.
Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049–54.CrossRefPubMedPubMedCentral
20.
Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385(9986):2502–9.CrossRefPubMed
21.
Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatol. 2015;62(1):79–86.CrossRef
22.
Wilson EM, Kattakuzhy S, Sidharthan S, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62(3):280–8.CrossRefPubMed
23.
Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatol. 2015;61(6):1793–7.CrossRef
24.
Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol. 2015;62(S2):S192.CrossRef
25.
Osinusi A, Marti M, Kohli A, et al. Sofosbuvir/ledipasvir in retreatment of HCV genotype-1 patients who previously failed sofosbuvir/ribavirin therapy. [Abstract 011.] 49th Annual Meeting of the European Association for the Study of the Liver (EASL). April 9–13, 2014a; London, United Kingdom.
26.
Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.CrossRefPubMed
27.
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with Ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82.CrossRefPubMed
28.
Foster GR, Pianko S, Cooper C, et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. [Abstract L05.] 50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22–26, 2015; Vienna, Austria.
29.
Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49(4):634 – 51.CrossRefPubMed
30.
31.
Morrison TB, Wieland ML, Cha SS, et al. Disparities in preventative health services among Somali immigrants and refugees. J Immigr Minor Health. 2012;14(6):968–74.CrossRefPubMed
32.
Nguyen GC, Thuluvath PJ. Racial disparity of liver disease: biological, cultural, or socioeconomic factors. Hepatol. 2008;47(3):1058–66.CrossRef
33.
34.
35.
Dalgard O, Jeanssen S, Skaug K, et al. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38(8):864–70.CrossRefPubMed
36.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.CrossRefPubMed
37.
Jin R, Cai L, Tan M, et al. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. Am J Gastroenterol. 2012;107(11):1675–83.CrossRefPubMedPubMedCentral
Metadata
Title
Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community
Authors
Amber R. Tierney
William Huepfel
Aasma P. Shaukat
John R. Lake
Mark Boldt
Qi Wang
Mohamed A. Hassan
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of Immigrant and Minority Health / Issue 3/2019
Print ISSN: 1557-1912
Electronic ISSN: 1557-1920
DOI
https://doi.org/10.1007/s10903-018-0758-x

Other articles of this Issue 3/2019

Journal of Immigrant and Minority Health 3/2019 Go to the issue

Brief Communication

Uptake of Gynecological Cancer Screening and Performance of Breast Self-Examination Among 50-Year-Old Migrant and Non-migrant Women in Germany: Results of a Cross-Sectional Study (InEMa)

Brief Communication

Prevalence of Possible Mental Disorders in Syrian Refugees Resettling in the United States Screened at Primary Care

Review Paper

Cultural Considerations in the Assessment of Survivors of Torture

Original Paper

Bidimensional Acculturation and Psychological Distress in Pakistani Immigrant Women in Norway: A Cross-Sectional Study

Original Paper

Breast and Colorectal Cancer Screening Barriers Among Immigrants and Refugees: A Mixed-Methods Study at Three Community Health Centres in Toronto, Canada

Original Paper

Food and Nutrient Intakes of Jamaican Immigrants in Florida